Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OCH NCNP1

Next Previous
X
Search
Drug Profile

OCH NCNP1

Alternative Names: OCH; OCH-NCNP1

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Center of Neurology and Psychiatry
  • Class Glycolipids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 13 Apr 2024 Adverse events, efficacy and pharmacodynamics data from a phase-II trial in Multiple sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)
  • 11 Oct 2023 Efficacy and adverse events data from a phase II trial in Multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (Joint ECTRIMS-ACTRIMS 2023)
  • 31 May 2023 National Center of Neurology and Psychiatry completes a phase II trial in Multiple sclerosis in Japan (PO) (NCT04211740)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top